Domestic price of crizotinib

Crizotinib is a targeted drug mainly used to treat non-small cell lung cancer (NSCLC) with ALK (anaplastic lymphoma kinase) or ROS1 gene rearrangement. It prevents the growth and spread of cancer cells by inhibiting the activity of ALK and ROS1 enzymes. As a targeted drug, crizotinib provides a new treatment option for patients with advanced lung cancer, significantly improving the survival and quality of life of some patients.

Crizotinib is currently on the market in China and has been included in medical insurance, and patients can purchase it through hospital pharmacies. According to the medical insurance policies of different regions, patients may enjoy certain medical insurance reimbursement when purchasing, but please consult the local hospital pharmacy or medical insurance bureau for specific reimbursement ratios and prices. Under normal circumstances, the domestic price of crizotinib is about four to five thousand yuan, but due to differences in medical insurance policies in various places, the price may vary.

For patients who cannot purchase it through domestic channels, crizotinib can also be purchased overseas. There are two versions of crizotinib on the overseas market: original drug and generic version:

The original drug of crizotinib is produced by Pfizer (Pfizer), and the price is relatively high, about 1 yuan. Pfizer's original drugs have efficacy and safety verified by rigorous clinical trials, but due to higher prices, some patients may choose generic drugs as an alternative.

Generic drugs are produced by other pharmaceutical companies and have basically the same ingredients as the original drugs. There are mainly generic drugs from Bangladesh and Laos, which are relatively affordable, about one to two thousand yuan. Generic drugs are usually purchased through international drug procurement platforms or cross-border e-commerce, but patients should ensure that the purchasing channels are legal and reliable.

Although generic drugs are less expensive, they are basically the same as the brand-name drugs in terms of ingredients, therapeutic effects, etc., making them an affordable option for most patients.

Crizotinib, as a targeted therapy, provides a new treatment option for patients with non-small cell lung cancer. Domestic patients can purchase the drug through medical insurance, and original drugs and generic drugs in foreign markets also provide patients with more choices. Different purchasing channels and prices allow patients to choose appropriate treatment methods according to their own conditions.